Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis

A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases

Elena L. Paley

• Publisher: Academic Press
• Year: 2024
• Print ISBN:
  9780443288302
• eBook ISBN:
  9780443288319
• Topic: Biological Sciences
• Subtopic: Molecular Biology
• Index: Biological Sciences

Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis: A Conceptual Evolution of the Role of Microbiota Tryptamine in Human Diseases provides a detailed investigation into tryptamine, its underlying mechanisms, and metabolism across multiple diseases. The book explores key concepts of tryptamine, its biosynthetic pathways, and its influence in disease, specifically focusing on the Alzheimer's disease-associated gut bacterial sequence (ADAS). Various neurodegenerative conditions are covered alongside cancer, diabetes, infections, and chromosomal aberrations. Additionally, a chapter on gut tryptamine in domestic and agricultural animals is included. The book closes with case studies involving FDG-PET imaging in the context of tryptamine-treated mouse models and Alzheimer's disease patients.This book elucidates the implications of the gut microbiota-mediated tryptamine metabolism for human health, sharing insights into disease etiology, mechanisms, testing, prevention, and treatment. It is an ideal reference for researchers across the biomedical sciences. - Provides a detailed investigation into tryptamine and its role in human health - Explores the relationship between microbiome tryptamine metabolome and a range of diseases, including diabetes, cancer, Alzheimer's disease and Parkinson's disease - Considers the role of tryptamine in cell death and the impairment of genome activities - Paves the way for advances in disease prevention and treatment pathways

Table of contents

• Tryptamine Microbiota-Deregulated Aminoacyl-tRNA Biosynthesis
• Chapter 1 Introduction
• Chapter 2 Human gut microbial metabolite tryptamine inducing neurodegeneration causes chromosome and genome instability
• Chapter 3 Mutagenicity and genotoxicity of naturally occurring tryptamines and their principal metabolites
• Chapter 4 Abundant urinary tryptamine as an indicator of urinary tract infection and nosocomial infections
• Chapter 5 Proteus mirabilis, diseases, and tryptamine
• Chapter 6 Microbial tryptophan metabolites in cancer and leishmaniasis
• Chapter 7 The effect of human microbial metabolome on multisensory integration in aging and neurodegenerative diseases
• Chapter 8 Retinitis pigmentosa (RP): RP-causative gene mutations, RP-related gene mutations, mosaicism, and gut microbiome
• Chapter 9 The tRNA aminoacylation interference in diseases
• Chapter 10 Tryptamine interfere with cytochrome P450
• Chapter 11 Discovery of Alzheimer's disease-associated sequence and Caudoviricetes prophage markers in metagenomics of type 2 diabetes and associated medical conditions
• Chapter 12 Tryptamine, ADAS and microbiome in Parkinson's disease
• Chapter 13 Microbial ADAS and tryptamine in domestic and agricultural animals
• Chapter 14 Tryptamine, stem cell/progenitor protein biosynthesis, and aminoacyl-tRNA biosynthesis
• Chapter 15 Tryptamine metabolite indole-3-acetic acid in neurodegenerative diseases and other conditions
• Chapter 16 FDG-PET: Tryptamine-treated mouse model and Alzheimer's disease patients. Conceptual evolution of microbiota tryptamine role in human diseases
• Chapter 17 Epilepsy, tryptamine-induced seizures, malfunction of ion channels, electrolyte abnormalities and antibiotic resistance
• Chapter 18 Conclusions
• Index